Clinical Trial Update: Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) [Phase 3]

View source ↗

Summary

Phase 3 trial results update comparing Temodal (temozolomide) with semustine in recurrent glioblastoma and anaplastic astrocytoma has been completed. The update…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma

Drugs mentioned

• Semustine (semustine)
• Temodal (temozolomide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Glioblastoma, Astrocytoma | Phase 3 | Status: COMPLETED